Research And Markets Research And Markets
0 CHECKOUT

Cachexia - Pipeline Review, H2 2015

  • ID: 3455196
  • September 2015
  • 158 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Acacia Pharma Limited
  • Aphios Corporation
  • GTx, Inc.
  • KAEL-GemVax Co., Ltd.
  • Novartis AG
  • Radius Health, Inc.
  • MORE

Cachexia - Pipeline Review, H2 2015

Summary

The report ‘Cachexia - Pipeline Review, H2 2015’, provides an overview of the Cachexia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cachexia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cachexia and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Acacia Pharma Limited
  • Aphios Corporation
  • GTx, Inc.
  • KAEL-GemVax Co., Ltd.
  • Novartis AG
  • Radius Health, Inc.
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Cachexia Overview

Therapeutics Development

Pipeline Products for Cachexia - Overview

Pipeline Products for Cachexia - Comparative Analysis

Cachexia - Therapeutics under Development by Companies

Cachexia - Therapeutics under Investigation by Universities/Institutes

Cachexia - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Cachexia - Products under Development by Companies

Cachexia - Products under Investigation by Universities/Institutes

Cachexia - Companies Involved in Therapeutics Development

Acacia Pharma Limited

Aeterna Zentaris Inc.

Amgen Inc.

Aphios Corporation

Atara Biotherapeutics, Inc.

Connexios Life Sciences Pvt. Ltd.

Eli Lilly and Company

GlaxoSmithKline Plc

GTx, Inc.

Helsinn Healthcare S.A.

Incyte Corporation

KAEL-GemVax Co., Ltd.

MI.TO. Technology S.r.L.

Myos Corporation

Novartis AG

Obexia AG

PolyNovo Limited

PsiOxus Therapeutics Limited

Radius Health, Inc.

RaQualia Pharma Inc.

Rhythm Pharmaceuticals

VBS Pharmaceuticals

Vicus Therapeutics, LLC

Viking Therapeutics, Inc.

Cachexia - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(etodolac + propranolol hydrochloride) - Drug Profile

(formoterol fumarate + megestrol acetate) - Drug Profile

anamorelin hydrochloride - Drug Profile

Antibody to Inhibit Parathyroid Hormone Related Protein for Cancer Cachexia - Drug Profile

AOD-9604 - Drug Profile

Aptamer to Activate Calcineurin A for Genetic Disorders and Musculoskeletal Disorders - Drug Profile

ARM-210 - Drug Profile

ATA-842 - Drug Profile

AV-380 - Drug Profile

bimagrumab - Drug Profile

C-1889 - Drug Profile

CAR Peptide - Drug Profile

CNX-013B2 - Drug Profile

DLN-101 - Drug Profile

dronabinol - Drug Profile

Drug to Antagonize ActRIIB for Cancer Cachexia - Drug Profile

enobosarm - Drug Profile

Espindolol - Drug Profile

EXT-400 - Drug Profile

GSK-2881078 - Drug Profile

landogrozumab - Drug Profile

macimorelin acetate - Drug Profile

Monoclonal Antibody to Antagonize TWEAK Receptor for Cachexia and Cancer Cachexia - Drug Profile

NBD Peptide - Drug Profile

OBX-1201 - Drug Profile

Proteins for Musculoskeletal Disorders - Drug Profile

RAD-140 - Drug Profile

relamorelin - Drug Profile

RQ-00432933 - Drug Profile

ruxolitinib phosphate - Drug Profile

Small Molecule to Agonize Ghrelin Receptor for Cancer Cachexia and Anorexia - Drug Profile

Small Molecule to Inhibit ATGL for Cancer Cachexia and Type 2 Diabetes - Drug Profile

Small Molecules to Inhibit Furin for Sarcopenia and Cachexia - Drug Profile

Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis, Sarcopenia and Cachexia - Drug Profile

Small Molecules to Inversely Agonize Beta3-Adrenoreceptor for Cachexia, Metabolic Syndrome and Heart Failure - Drug Profile

Small Molecules to Target Melanocortin-4 Receptor for Cachexia - Drug Profile

Synthetic Peptide to Inhibit Melanocortin Receptor for Cancer Cachexia - Drug Profile

Synthetic Peptides for Cancer Cachexia - Drug Profile

tertomotide - Drug Profile

VK-5211 - Drug Profile

Cachexia - Recent Pipeline Updates

Cachexia - Dormant Projects

Cachexia - Discontinued Products

Cachexia - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Cachexia, H2 2015

Number of Products under Development for Cachexia - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Comparative Analysis by Unknown Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Development by Companies, H2 2015 (Contd..1)

Products under Development by Companies, H2 2015 (Contd..2)

Products under Investigation by Universities/Institutes, H2 2015

Cachexia - Pipeline by Acacia Pharma Limited, H2 2015

Cachexia - Pipeline by Aeterna Zentaris Inc., H2 2015

Cachexia - Pipeline by Amgen Inc., H2 2015

Cachexia - Pipeline by Aphios Corporation, H2 2015

Cachexia - Pipeline by Atara Biotherapeutics, Inc., H2 2015

Cachexia - Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2015

Cachexia - Pipeline by Eli Lilly and Company, H2 2015

Cachexia - Pipeline by GlaxoSmithKline Plc, H2 2015

Cachexia - Pipeline by GTx, Inc., H2 2015

Cachexia - Pipeline by Helsinn Healthcare S.A., H2 2015

Cachexia - Pipeline by Incyte Corporation, H2 2015

Cachexia - Pipeline by KAEL-GemVax Co., Ltd., H2 2015

Cachexia - Pipeline by MI.TO. Technology S.r.L., H2 2015

Cachexia - Pipeline by Myos Corporation, H2 2015

Cachexia - Pipeline by Novartis AG, H2 2015

Cachexia - Pipeline by Obexia AG, H2 2015

Cachexia - Pipeline by PolyNovo Limited, H2 2015

Cachexia - Pipeline by PsiOxus Therapeutics Limited, H2 2015

Cachexia - Pipeline by Radius Health, Inc., H2 2015

Cachexia - Pipeline by RaQualia Pharma Inc., H2 2015

Cachexia - Pipeline by Rhythm Pharmaceuticals, H2 2015

Cachexia - Pipeline by VBS Pharmaceuticals, H2 2015

Cachexia - Pipeline by Vicus Therapeutics, LLC, H2 2015

Cachexia - Pipeline by Viking Therapeutics, Inc., H2 2015

Assessment by Monotherapy Products, H2 2015

Assessment by Combination Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Cachexia Therapeutics - Recent Pipeline Updates, H2 2015

Cachexia - Dormant Projects, H2 2015

Cachexia - Dormant Projects (Contd..1), H2 2015

Cachexia - Dormant Projects (Contd..2), H2 2015

Cachexia - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Cachexia, H2 2015

Number of Products under Development for Cachexia - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

Acacia Pharma Limited
Aeterna Zentaris Inc.
Amgen Inc.
Aphios Corporation
Atara Biotherapeutics, Inc.
Connexios Life Sciences Pvt. Ltd.
Eli Lilly and Company
GlaxoSmithKline Plc
GTx, Inc.
Helsinn Healthcare S.A.
Incyte Corporation
KAEL-GemVax Co., Ltd.
MI.TO. Technology S.r.L.
Myos Corporation
Novartis AG
Obexia AG
PolyNovo Limited
PsiOxus Therapeutics Limited
Radius Health, Inc.
RaQualia Pharma Inc.
Rhythm Pharmaceuticals
VBS Pharmaceuticals
Vicus Therapeutics, LLC
Viking Therapeutics, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

RELATED PRODUCTS from Db